Study of progesterone-induced blocking factor in the treatment of women with threatening abortion, taking into account the polymorphism of the progesterone receptor gene.
Keywords:threatened abortion, progesterone receptor gene polymorphism, progesterone induced blocking factor, natural micronized progesterone therapy
Actual medical and social problem of modern obstetrics is threatening abortion. In its treatment, analogues of progesterone are used. Activation of progesterone receptors induces the production of anti-abortive protein-progesterone-induced blocking factor (PIBF). The dynamics of PIBF in 28 patients with the diagnosis of threatening abortion was analyzed. Women were treated by natural micronized progesterone depending on the features of the clinical course and single nucleotide polymorphism of the progesterone receptor gene rs590688. The quantitative content of PIBF in urine in pregnant women with threatening abortion was determined, namely, the increase in the content of this factor is associated with the prolongation of pregnancy. At the time of initiation of therapy, the concentration of PIBP was 28.8±1.5 (95% CI 26.7-29.2) ng/ml, and on the 7th day of therapy its concentration was 29.4±0.1 (95% CI 29.2-29.5) ng/ml. The increase in PIBF has reached a degree of statistical significance (T-W=15.0, p<0.001). In 27 (96.4%) patients who were pregnant, PIBP levels increased, 1 (3.6%) patient had spontaneous miscarriage on the 9th day of treatment. She had a decrease in concentration of PIBF in urine from 29.18 ng/ml at the time of admission to the hospital to 28.58 ng/ml on the 7th day of therapy. The study of progesterone-induced-blocking factor can be considered as an additional laboratory method of controlling progesterone therapy in women with threatening abortion in specialized research institutions.
Vovk IB, Vdovychenko YP, Trokhymovych OV. [Early reproductive loss]. Kyiv. 2016;253. Ukrainian.
Gnatko OP, Kryvopustov OS. [Threatened abortion treatment efficacy depending on progesterone receptor gene polymorphism]. Bukov. med. visn. 2017;21(1):44-8. Ukrainian.
Gnatko OP, Kryvopustov OS. [Effectiveness of evaluation of progesterone therapy in women with threatened abortion based on clinical approach and single nucleotide polymorphism progesterone gene receptor rs590688]. Eksperym. i klin. medytsyna. 2017;1:71-6. Ukrainian.
Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev. 1990;11(2):266-301.
Dosiou C, Giudice LC. Natural killer cells in pregnancy and recurrent pregnancy loss: endocrine and immunologic perspectives. Endocr Rev. 2005;26(1):44-62.
Kelemen K, Bognar I, Paal M, Szekeres-Bartho J. A progesterone-induced protein increases the synthesis of asymmetric antibodies. Cell Immunol. 1996;167(1):129-34.
Manuck TA, Lai Y, Meis PJ, Dombrowski MP, Sibai B, Spong CY, et al. Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 2011;205(2):135.e1-9.
Raghupathy R, Al-Mutawa E, Al-Azemi M, Makhseed M, Azizieh F, Szekeres-Bartho J. Progesterone-induced blocking factor (PIBF) modulates cytokine production by lymphocytes from women with recurrent miscarriage or preterm delivery. J Reprod Immunol. 2009;80(1/2):91-9.
Romano A, Delvoux B,FischerDC, Groothuis P. The PROGINS polymorphism of the human progesterone receptor diminishes the response to progesterone. J Mol Endocrinol. 2007;38(1/2):331-50.
Szekeres-Bartho J, Wegmann TG. A progesterone-dependent immunomodulatory protein alters the Th1/Th2 balance. J Reprod Immunol. 1996;31(1/2):81-95.
Wahabi HA, Abed Althagafi NF, Elawad M, Al Zeidan RA. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev. 2011;16(3):CD005943.
How to Cite
Copyright (c) 2017 Medicni perspektivi (Medical perspectives)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.